AngioDynamics CFO granted new equity awards

Trowbridge Stephen A reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Trowbridge Stephen A reported acquisition or exercise transactions in this Form 4 filing.

AngioDynamics EVP and CFO Stephen A. Trowbridge received equity awards on July 15, 2026. He was granted 53,257 restricted stock units, vesting in four equal annual installments each July 15 from 2027 through 2030, and 53,257 performance rights, each a contingent right to one share of common stock. Payout on the performance rights can range from 0% up to 240% of the target, based on relative total shareholder return over a three-year performance period. After the restricted stock unit award, his directly held common stock reported in this line totals 297,819 shares.

Insider Trade Summary

Grant/Award: 106,514 shares

Grant/Award 2 txns

Insider Trowbridge Stephen A

Role EVP and CFO

Type	Security	Shares	Price	Value
Grant/Award	Performance Right F2	53,257	$0.00	$0.00
Grant/Award	Common Stock F1	53,257	$0.00	$0.00

Holdings After Transaction: Performance Right — 53,257 contracts (Direct); Common Stock — 297,819 shares (Direct)

Footnotes (2)

1. F1. The acquisition of 53,257 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 53,257 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.
2. F2. Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

Key Figures

Restricted stock units granted: 53,257 units Performance rights granted (target): 53,257 rights RSU vesting pattern: 25% annually +2 more

5 metrics

Restricted stock units granted 53,257 units Awarded to EVP and CFO Stephen A. Trowbridge on July 15, 2026

Performance rights granted (target) 53,257 rights Each performance right represents a contingent right to receive one share of Common Stock

RSU vesting pattern 25% annually Restricted stock units vest in four equal annual installments each July 15 from 2027 through 2030

Maximum payout vs target 240% of target Total potential payout for performance rights based on three-year total shareholder return relative to a peer group

Direct common stock after award 297,819 shares Directly held common stock reported following the July 15, 2026 restricted stock unit grant

Key Terms

restricted stock units, performance right, total shareholder return, peer group of companies, +1 more

5 terms

restricted stock units financial

"represents 53,257 restricted stock units, each of which represents"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

performance right financial

"Each performance right represents a contingent right to receive"

total shareholder return financial

"earned based on total shareholder return relative to a peer group"

Total shareholder return is the overall gain an investor gets from owning a stock, combining changes in the share price plus any cash payouts like dividends, and assuming those payouts are reinvested in more shares. Investors use it like a single score that shows the true return on their investment—similar to checking both the growth of a savings account and the interest earned—to compare how well different companies or investments perform over time.

peer group of companies financial

"relative to a peer group of companies over a three-year"

performance period financial

"over a three-year performance period in accordance with performance metrics"

The performance period is the specific time span over which an investment’s results, an employee’s targets, or a fund’s returns are measured and judged. It matters to investors because the length and start/end of that window determine which gains or losses count toward performance fees, bonus payouts, or benchmark comparisons—much like timing a race decides who wins, the chosen period can change whether results look strong or weak.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did AngioDynamics (ANGO) CFO Stephen A. Trowbridge receive?

Stephen A. Trowbridge received 53,257 restricted stock units and 53,257 performance rights on July 15, 2026. Each unit or right represents a contingent right to receive one share of AngioDynamics common stock, subject to time-based vesting and performance conditions.

How do the restricted stock units for AngioDynamics (ANGO) CFO vest?

The 53,257 restricted stock units vest in four equal annual installments of 25% each. Vesting occurs on July 15 of 2027, 2028, 2029 and 2030, assuming the applicable service conditions are satisfied at each vesting date.

What determines the payout of the AngioDynamics (ANGO) performance rights granted to the CFO?

Each performance right is tied to total shareholder return versus a peer group over a three-year period. The payout can range from 0% to a maximum of 240% of the target number, with unearned shares forfeited at the end of the performance period.

How many AngioDynamics (ANGO) shares does the CFO hold after these awards?

Following the restricted stock unit grant, Trowbridge’s directly held common stock reported in the non-derivative table totals 297,819 shares. This reflects his position as of the July 15, 2026 transaction, as disclosed in the Form 4 data.

Were the AngioDynamics (ANGO) CFO’s equity awards made under a Rule 10b5-1 trading plan?

The Form 4 data indicate the Rule 10b5-1 checkbox is not marked as an affirmative plan. No accompanying footnote describes these equity awards as being executed under a Rule 10b5-1 or other pre-arranged trading plan.

What happens to AngioDynamics (ANGO) CFO performance rights that do not vest?

Any performance rights that are not earned at the end of the three-year performance period are forfeited. The number earned depends on total shareholder return relative to a peer group, including a potential 20% upward or downward adjustment to calculated achievement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/22/2026 - 08:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trowbridge Stephen A

(Last) (First) (Middle)

14 PLAZA DRIVE

(Street)

LATHAM NEW YORK 12110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		A		53,257(1)	A	$0	297,819	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Right	(2)	07/15/2026		A		53,257		(2)	(2)	Common Stock	53,257	$0	53,257	D

Explanation of Responses:

1. The acquisition of 53,257 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 53,257 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.

2. Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

	/s/ Lawrence T. Weiss, as Attorney in Fact	07/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)